These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer. Kucuk A, Topkan E, Ozkan EE, Ozturk D, Pehlivan B, Selek U. Int J Immunopathol Pharmacol; 2023 Dec 13; 37():3946320231187759. PubMed ID: 37404137 [Abstract] [Full Text] [Related]
7. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma. Su Z, Tang J, He Y, Zeng WH, Yu Q, Cao XL, Zou GR. Oncol Lett; 2024 Jun 13; 27(6):252. PubMed ID: 38646495 [Abstract] [Full Text] [Related]
8. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, Morano F, Spallanzani A, Ambrosini M, Curigliano G, de Braud F, Zagonel V, Fucà G, Pietrantonio F. Eur J Cancer; 2021 Jun 13; 150():155-167. PubMed ID: 33901794 [Abstract] [Full Text] [Related]
9. Association of the panimmune-inflammatory value (PIV) with all-cause and cardiovascular mortality in maintenance hemodialysis patients: a propensity score matching retrospective study. Li C, Wen Q, Zhu G, Zhang Y, Wang Y, Luo D, Wu J. Int Urol Nephrol; 2024 Sep 10. PubMed ID: 39254905 [Abstract] [Full Text] [Related]
10. Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer. Zhou M, Wang D, Long Z, Zhang Y, Liu J. J Cancer; 2020 Sep 10; 11(4):983-989. PubMed ID: 31949501 [Abstract] [Full Text] [Related]
11. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients. Zhang N, Hou T, Zhang S, Ling J, Jiang S, Xie Y, Liu X, Hu C, Feng Y. Heliyon; 2024 Jan 30; 10(2):e24804. PubMed ID: 38312571 [Abstract] [Full Text] [Related]
12. Effect of preoperative pan-immune-inflammation value on clinical and oncologic outcomes after colorectal cancer surgery: a retrospective study. Seo YJ, Kim KE, Jeong WK, Baek SK, Bae SU. Ann Surg Treat Res; 2024 Mar 30; 106(3):169-177. PubMed ID: 38435496 [Abstract] [Full Text] [Related]
13. Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy. Chen Y, Gong L, Gu P, Hua Y, Sun Y, Ni S, Zhou X, Tang Z. BMC Cancer; 2023 Oct 06; 23(1):944. PubMed ID: 37803437 [Abstract] [Full Text] [Related]
14. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Chen X, Hong X, Chen G, Xue J, Huang J, Wang F, Ali WADS, Li J, Zhang L. Transl Oncol; 2022 Mar 06; 17():101338. PubMed ID: 34999541 [Abstract] [Full Text] [Related]
15. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis. Lien MY, Hwang TZ, Wang CC, Hsieh CY, Yang CC, Wang CC, Lien CF, Shih YC, Yeh SA, Hsieh MC. Target Oncol; 2024 Jan 06; 19(1):71-79. PubMed ID: 38041732 [Abstract] [Full Text] [Related]
16. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy. Zhang Y, Chen Z, Jin F, Guo D, Chen Q, Liu Z, Ji S, Gao G. Mediators Inflamm; 2021 Jan 06; 2021():2910892. PubMed ID: 34744510 [Abstract] [Full Text] [Related]
17. Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas). Yang Y, Hu F, Wu S, Huang Z, Wei K, Ma Y, Ou-Yang Q. Front Neurol; 2023 Jan 06; 14():1297835. PubMed ID: 37936915 [Abstract] [Full Text] [Related]
18. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer. Karadağ I, Karakaya S, Yılmaz ME, Çakmak Öksüzoğlu ÖB. Eur Rev Med Pharmacol Sci; 2022 Oct 06; 26(20):7679-7686. PubMed ID: 36314339 [Abstract] [Full Text] [Related]
19. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer. Kayar R, Bastug Y, Tokuc E, Topaktas R, Akyurek EA, Kayar K, Artuk I, Ozturk M. Int Urol Nephrol; 2024 Feb 06; 56(2):509-518. PubMed ID: 37773579 [Abstract] [Full Text] [Related]
20. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients. Zeng R, Liu F, Fang C, Yang J, Luo L, Yue P, Gao B, Dong Y, Xiang Y. Front Immunol; 2021 Feb 06; 12():724443. PubMed ID: 34777341 [Abstract] [Full Text] [Related] Page: [Next] [New Search]